Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
IPO Year:
Exchange: NYSE
Website: bauschhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $8.00 | Equal Weight | Barclays |
| 8/2/2024 | $9.00 → $3.00 | Neutral → Underweight | Piper Sandler |
| 7/10/2024 | $8.00 | Mkt Perform | Raymond James |
| 9/20/2023 | $9.00 → $16.00 | Hold → Buy | Jefferies |
| 6/16/2023 | Outperform → Market Perform | TD Cowen | |
| 7/29/2022 | Buy → Hold | Truist | |
| 7/29/2022 | $12.00 → $5.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/28/2022 | Overweight → Neutral | JP Morgan | |
| 6/13/2022 | $12.00 | Overweight | JP Morgan |
| 11/3/2021 | $41.00 → $40.00 | Outperform | RBC Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
SD - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)
DEF 14A - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00
Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously
Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00
Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously
TD Cowen downgraded Bausch Health from Outperform to Market Perform
Truist downgraded Bausch Health from Buy to Hold
RBC Capital Mkts downgraded Bausch Health from Outperform to Sector Perform and set a new price target of $5.00 from $12.00 previously
JP Morgan downgraded Bausch Health from Overweight to Neutral
JP Morgan resumed coverage of Bausch Health with a rating of Overweight and set a new price target of $12.00
RBC Capital reiterated coverage of Bausch Health Companies with a rating of Outperform and set a new price target of $40.00 from $41.00 previously
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
Fastest customizable press release news feed in the world
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,
LAVAL, QC, May 13, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate: Wednesday, May 20, 2026Time: 9:30 a.m. U.S. ETWebcast: http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following t
LAVAL, QC, May 12, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate: Tuesday, May 19, 2026Time: 10:25 a.m. U.S. ETWebcast: http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following the event.About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global,
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channelsLAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.First developed in France in 1971, Biafine® is a lightweight emulsion formula designed to support the skin's natural barrier function while helping to maintain skin hydration and comfort. For decades, the formula has been recognized by dermatol
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate: Wednesday, April 29, 2026Time: 5:00 p.m. U.S. EDTWebcast: http://ir.bauschhealth.com/events-and-
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS
LAVAL, QC, Feb. 23, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable s
The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical useLAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.Dan Wu, Ph
Live finance-specific insights
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate: Wednesday, April 29, 2026Time: 5:00 p.m. U.S. EDTWebcast: http://ir.bauschhealth.com/events-and-
Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y
LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Conference Call Details Date: Wednesday, February 18, 2026Time: 5:00 p.m. U.S. ESTWebcast: http://ir.bauschhealth.com/events-and-presentations A replay of the conference call will be available on the investor rel
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, August 1, 2024Time:8:00 a.m. U.S. ESTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13%Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + LombReaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financia
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Thursday, May 2, 2024Time:8:00 a.m. U.S. EDTWebcast:http://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in the live Q&A session, please regis
Live Leadership Updates
LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,
LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing
Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum DiseaseCollaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex RodriguezLAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community.Gum disease, also known as periodont
Kimball Electronics, Inc. (NASDAQ:KE), announces the expansion of its Board of Directors and appointment of a new director at its regularly scheduled Board Meeting on September 13, 2022. Tom Vadaketh was selected to the Company's Board of Directors (the "Board"), effective as of the September meeting. Mr. Vadaketh will serve on the Audit Committee and will stand for election to a full term at the 2022 Annual Meeting of Share Owners in November. Mr. Vadaketh serves as Chief Financial Officer of Bausch Health (NYSE:BHC) (TSX:BHC), which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices globally, primarily in the therapeutic areas of eye-heal
Biotech Leader Brent Saunders Named Chairman of Board Robert Ruffolo, Ph.D, and Robin Steele Named Board Members OcuTerra Therapeutics, Inc. ("OcuTerra"), a clinical stage ophthalmology drug development company focused on treating diabetic retinopathy earlier to preserve vision and avoid intravitreal injections, today announced the appointment of Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors. Brent Saunders will serve as Chairman and William H. Koster, Ph.D, will remain on the Board as Vice Chair. "The appointment of Brent as our Chairman and the addition of Bob and Robin to our Board underscores the momentum and growth of OcuTerra. A recognized biotec
This live feed shows all institutional transactions in real time.
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)